Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
October 6, 2015 7:50 AM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening.
U.S. Preventive Services Task Force Webcast and Conference Call Details
  Date:  Tuesday, Oct. 6, 2015 Time: 9 a.m. ET, 8 a.m. CT... MoreCologuard® Included as Alternative Screening Test under Draft USPSTF Guidelines
October 5, 2015 8:21 PM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.
USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an A rating for colorectal cancer screening starting at age 50 and continuing until age 75.... More
